After ovarian cancer cells were treated with WZ10, there was a dose-dependent, significant downregulation in the expressions of cyclin, Oct-4 and vimentin, suggesting that WZ10 treatment could inhibit the activation of the Hippo-YAP pathway. Here, POU5F1 is linked to ovarian carcinoma.